NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Forecast, Price & News $9.27 -0.29 (-3.03%) (As of 12:55 PM ET) Add Compare Share Share Today's Range$9.13▼$9.4050-Day Range$8.95▼$12.5452-Week Range$8.06▼$25.47Volume2,067 shsAverage Volume39,506 shsMarket Capitalization$204.59 millionP/E RatioN/ADividend YieldN/APrice Target$22.86 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acrivon Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.4% Upside$22.86 Price TargetShort InterestBearish2.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.16Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.64) to ($3.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector668th out of 969 stocksPharmaceutical Preparations Industry319th out of 453 stocks 3.5 Analyst's Opinion Consensus RatingAcrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.86, Acrivon Therapeutics has a forecasted upside of 143.4% from its current price of $9.39.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.80% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 24.6, which indicates bearish sentiment.Change versus previous monthShort interest in Acrivon Therapeutics has recently decreased by 0.03%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRV. Previous Next 2.9 News and Social Media Coverage News SentimentAcrivon Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acrivon Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Acrivon Therapeutics is held by insiders.Percentage Held by Institutions68.54% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.64) to ($3.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Acrivon Therapeutics (NASDAQ:ACRV) StockAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.Read More ACRV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRV Stock News HeadlinesSeptember 29, 2023 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 24, 2023 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Buy" by BrokeragesOctober 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.September 19, 2023 | finance.yahoo.comAcrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 5, 2023 | finance.yahoo.comAcrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical StudiesAugust 30, 2023 | finance.yahoo.comAcrivon Therapeutics to Participate in Two Investor Conferences in SeptemberAugust 18, 2023 | msn.comJonesTrading Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy RecommendationAugust 17, 2023 | finance.yahoo.comAcrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.August 11, 2023 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 11, 2023 | finance.yahoo.comAcrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsJuly 20, 2023 | finance.yahoo.comAcrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate AffairsJune 22, 2023 | finance.yahoo.comAcrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of DirectorsJune 15, 2023 | benzinga.comAcrivon Therapeutics 10% Owner Trades Company's StockJune 2, 2023 | finance.yahoo.comAcrivon Therapeutics to Present at the Jefferies Healthcare ConferenceMay 10, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Acrivon Therapeutics, Inc. (ACRV)May 9, 2023 | finance.yahoo.comQ1 2023 Akoya Biosciences Inc Earnings CallMay 9, 2023 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsMay 9, 2023 | finance.yahoo.comAcrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial CancerMay 9, 2023 | finance.yahoo.comAcrivon Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsMay 9, 2023 | markets.businessinsider.comAcrivon Therapeutics, Inc. (ACRV) Receives a Buy from BMO CapitalMay 7, 2023 | finance.yahoo.comWe Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business GrowthMay 3, 2023 | msn.comHC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy RecommendationApril 25, 2023 | finance.yahoo.comAcrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor ConferenceApril 24, 2023 | finance.yahoo.comAcrivon Therapeutics to Host Virtual Investor Event on May 1, 2023April 20, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy RecommendationApril 18, 2023 | finance.yahoo.comAcrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days ConferenceSee More Headlines Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Company Calendar Last Earnings8/11/2023Today10/02/2023Next Earnings (Estimated)12/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRV CUSIPN/A CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.86 High Stock Price Forecast$26.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+139.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($7.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.24% Return on Assets-29.91% Debt Debt-to-Equity RatioN/A Current Ratio21.84 Quick Ratio21.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.16 per share Price / Book1.17Miscellaneous Outstanding Shares22,073,000Free Float20,462,000Market Cap$211.02 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Peter Blume-Jensen M.D. (Age 60)Ph.D., Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer Comp: $1.01MMs. Kristina Masson M.B.A. (Age 42)Ph.D., Co-Founder, Exec. VP of Bus. Operations, Site Head, Treasurer, Sec. & Director Mr. Rasmus Holm-Jorgensen (Age 52)Chief Financial Officer Comp: $1MDr. Eric J. Devroe Ph.D. (Age 45)Chief Operating Officer Comp: $614.78kMs. Katharine Peterson CPAVP of Fin. & AccountingDr. Adam D. Levy M.B.A.Ph.D., Sr. VP and Head of Investor Relations & Corp. AffairsMr. Bruce CloseVP of Quality & ComplianceMs. Mary-Alice Miller J.D. (Age 49)Gen. Counsel Ms. Parvin MiahVP & Head of HRMr. Erick Gamelin M.D. (Age 66)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLSagimet BiosciencesNASDAQ:SGMTCorMedixNASDAQ:CRMDLarimar TherapeuticsNASDAQ:LRMRALX OncologyNASDAQ:ALXOView All CompetitorsInsiders & InstitutionsBarclays PLCSold 2,720 shares on 9/21/2023Ownership: 0.065%Citadel Advisors LLCBought 8,624 shares on 8/15/2023Ownership: 7.522%Wells Fargo & Company MNBought 1,717 shares on 8/15/2023Ownership: 0.015%State Street CorpBought 40,637 shares on 8/14/2023Ownership: 0.574%Nuveen Asset Management LLCBought 11,821 shares on 8/14/2023Ownership: 0.054%View All Insider TransactionsView All Institutional Transactions ACRV Stock - Frequently Asked Questions Should I buy or sell Acrivon Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACRV shares. View ACRV analyst ratings or view top-rated stocks. What is Acrivon Therapeutics' stock price forecast for 2023? 9 Wall Street analysts have issued 1 year target prices for Acrivon Therapeutics' stock. Their ACRV share price forecasts range from $17.00 to $26.00. On average, they anticipate the company's share price to reach $22.86 in the next twelve months. This suggests a possible upside of 139.1% from the stock's current price. View analysts price targets for ACRV or view top-rated stocks among Wall Street analysts. How have ACRV shares performed in 2023? Acrivon Therapeutics' stock was trading at $11.52 at the beginning of 2023. Since then, ACRV stock has decreased by 17.0% and is now trading at $9.56. View the best growth stocks for 2023 here. When is Acrivon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023. View our ACRV earnings forecast. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) issued its earnings results on Friday, August, 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.02. What ETF holds Acrivon Therapeutics' stock ? Range Cancer Therapeutics ETF holds 10,409 shares of ACRV stock, representing 1.23% of its portfolio. When did Acrivon Therapeutics IPO? (ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. What is Acrivon Therapeutics' stock symbol? Acrivon Therapeutics trades on the NASDAQ under the ticker symbol "ACRV." How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acrivon Therapeutics' stock price today? One share of ACRV stock can currently be purchased for approximately $9.56. How much money does Acrivon Therapeutics make? Acrivon Therapeutics (NASDAQ:ACRV) has a market capitalization of $211.02 million. The company earns $-31,170,000.00 in net income (profit) each year or ($7.18) on an earnings per share basis. How can I contact Acrivon Therapeutics? The official website for the company is www.acrivon.com. The company can be reached via phone at 617-207-8979 or via email at asantos@wheelhouselsa.com. This page (NASDAQ:ACRV) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.